The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Martagón, Alexandro J ^a,b   Lin, Jean Z ^a,c   Cimini, Stephanie L ^a   Webb, Paul ^a   Phillips, Kevin J ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPROTIROME; HORMONE RECEPTOR STIMULATING AGENT; LIOTHYRONINE; SOBETIROME; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 3-((3,5-DIBROMO-4-(4-HYDROXY-3-(1-METHYLETHYL)PHENOXY)PHENYL)AMINO)-3-OXOPROPANOIC ACID; ACETIC ACID DERIVATIVE; ANILIDE; GLUCOSE 6 PHOSPHATASE; GLUCOSE BLOOD LEVEL; PHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER LEVEL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OB/OB MOUSE; AGONISTS; ANIMAL; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECTS; ENZYME INDUCTION; METABOLISM; MOUSE MUTANT; NON-ALCOHOLIC FATTY LIVER DISEASE; TIME FACTOR;

MUS;

ACETATES; ANILIDES; ANIMALS; BLOOD GLUCOSE; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GLUCOSE-6-PHOSPHATASE; INSULIN RESISTANCE; MALE; MICE; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOLS; RECEPTORS, THYROID HORMONE; TIME FACTORS;

EID: 84927551485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122987     Document Type: Article

References (43)

1. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114: 147-152. doi: 10.1172/JCI200422422 PMID: 15254578
2. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc J. 2005; 172: 899-905. doi: 10.1503/cmaj.045232
3. Cohen JC, Horton JD, Hobbs HH. Human Fatty Liver Disease: Old Questions and New Insights. Science. 2011; 332: 1519-1523. doi: 10.1126/science.1204265 PMID: 21700865
4. Samuel VT, Shulman GI. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012; 148: 852-871. doi: 10.1016/j.cell.2012.02.017 PMID: 22385956
5. Wei Y, Clark SE, Thyfault JP, Uptergrove GME, Li W, Whaley-Connell AT, et al. Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats. Am J Pathol. 2009; 174: 1329-1337. doi: 10.2353/ajpath.2009.080697 PMID: 19246643
6. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53: 372-384. doi: 10.1016/j.jhep.2010.04.008 PMID: 20494470
7. Charlton M. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001; 7: 608-614. doi: 10.1053/jlts.2001.25453 PMID: 11460228
8. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7: 363-373. doi: 10.1053/jlts.2001.23011 PMID: 11303298
9. Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol. 2009; 8: S51-S59. PMID: 19381125
10. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009; 8: 308-320. doi: 10.1038/nrd2830 PMID: 19337272
11. Lin JZ, Martagon AJ, Hsueh WA, Baxter JD, Gustafsson J-A, Webb P, et al. Thyroid Hormone Receptor Agonists Reduce Serum Cholesterol Independent of the LDL Receptor. Endocrinology. 2012; 153: 6136-6144. doi: 10.1210/en.2011-2081 PMID: 23087171
12. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology. 2009; 49: 407-417. doi: 10.1002/hep.22572 PMID: 19072834
13. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, et al. Thyroid hormone (T3) and TR agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J. 2008; 22: 2981-2989. doi: 10.1096/fj.08-108464 PMID: 18434432
14. Dimitriadis GD, Raptis SA. Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Amp Diabetes. 2001; 109: S225-S239. doi: 10.1055/s-2001-18584 PMID: 11460573
15. Stefan N, Kantartzis K, Haring H-U. Causes and Metabolic Consequences of Fatty Liver. Endocr Rev. 2008; 29: 939-960. doi: 10.1210/er.2008-0009 PMID: 18723451
16. Rohdenburg GL. Thyroid Diabetes. Endocrinology. 1920; 4: 63-70. doi: 10.1210/endo-4-1-63
17. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, et al. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol. 2008; 111: 262-267. doi: 10.1016/j.jsbmb.2008.06.010 PMID: 18621127
18. Höppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, et al. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia. 1999; 42: 427-434. doi: 10.1007/s001250051175 PMID: 10230646
19. JAX NOTES: Variation in the Severity and Duration of Hyperglycemia in the C - The Jackson Laboratory [Internet]. [cited 17 Feb 2014]. Available: http://jaxmice.jax.org/jaxnotes/archive/451b.html
20. F O, M U. Metabolism of glucose in hyper- and hypo-thyroid rats in vivo. Glucose-turnover values and futile-cycle activities obtained with 14C- and 3H-labelled glucose. [Internet]. 15 Aug 1979 [cited 23 Oct 2013]. Available: http://www.biochemj.org/bj/182/bj1820565.htm
21. Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol. 2000; 14: 947-955. PMID: 10894146
22. Moller MJ, Seitz HJ. Rapid and direct stimulation of hepatic gluconeogenesis by L-triiodothyronine (T3) in the isolated-perfused rat liver. Life Sci. 1980; 27: 827-835. doi: 10.1016/0024-3205(80)90076-4 PMID: 6251328
23. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997; 5: 177-269.
24. Vujovic M, Nordström K, Gauthier K, Flamant F, Visser TJ, Vennström B, et al. Interference of a Mutant Thyroid Hormone Receptor α1 with Hepatic Glucose Metabolism. Endocrinology. 2009; 150: 2940-2947. doi: 10.1210/en.2008-1085 PMID: 19282388
25. Sun Z, Lazar MA. Dissociating fatty liver and diabetes. Trends Endocrinol Metab. 2013; 24: 4-12. doi: 10.1016/j.tem.2012.09.005 PMID: 23043895
26. Hammond LE. Mitochondrial Glycerol-3-phosphate Acyltransferase-1 Is Essential in Liver for the Metabolism of Excess Acyl-CoAs. J Biol Chem. 2005; 280: 25629-25636. doi: 10.1074/jbc.M503181200 PMID: 15878874
27. Wendel AA, Li LO, Li Y, Cline GW, Shulman GI, Coleman RA. Glycerol-3-Phosphate Acyltransferase 1 Deficiency in ob/ob Mice Diminishes Hepatic Steatosis but Does Not Protect Against Insulin Resistance or Obesity. Diabetes. 2010; 59: 1321-1329. doi: 10.2337/db09-1380 PMID: 20200319
28. Flowers JB, Rabaglia ME, Schueler KL, Flowers MT, Lan H, Keller MP, et al. Loss of Stearoyl-CoA Desaturase-1 Improves Insulin Sensitivity in Lean Mice but Worsens Diabetes in Leptin-Deficient Obese Mice. Diabetes. 2007; 56: 1228-1239. doi: 10.2337/db06-1142 PMID: 17369521
29. Vatner DF, Weismann D, Beddow SA, Kumashiro N, Erion DM, Liao X-H, et al. Thyroid hormone receptor- agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. AJP Endocrinol Metab. 2013; 305: E89-E100. doi: 10.1152/ajpendo.00573.2012 PMID: 23651850
30. Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, et al. Thyroid Hormone Induced Brown Adipose Tissue and Amelioration of Diabetes in a Patient with Extreme Insulin Resistance. J Clin Endocrinol Metab. 2009; 95: 256-262. doi: 10.1210/jc.2009-0543 PMID: 19897683
31. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, et al. Targeting thyroid hormone receptor-βagonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci. 2007; 104: 15490-15495. PMID: 17878314
32. Trinh KY. Perturbation of Fuel Homeostasis Caused by Overexpression of the Glucose-6-phosphatase Catalytic Subunit in Liver of Normal Rats. J Biol Chem. 1998; 273: 31615-31620. doi: 10.1074/jbc.273.47.31615 PMID: 9813078
33. Yuan C, Lin JZH, Sieglaff DH, Ayers SD, DeNoto-Reynolds F, Baxter JD, et al. Identical Gene Regulation Patterns of T3 and Selective Thyroid Hormone Receptor Modulator GC-1. Endocrinology. 2011; 153: 501-511. doi: 10.1210/en.2011-1325 PMID: 22067320
34. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature. 2000; 404: 652-660. doi: 10.1038/35007527 PMID: 10766252
35. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011; 17: 200-205. doi: 10.1038/nm.2297 PMID: 21258337
36. Nedergaard J, Bengtsson T, Cannon B. New powers of brown fat: fighting the metabolic syndrome. Cell Metab. 2011; 13: 238-240. doi: 10.1016/j.cmet.2011.02.009 PMID: 21356513
37. López M, Varela L, Vázquez MJ, Rodríguez-Cuenca S, González CR, Velagapudi VR, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med. 2010; 16: 1001-1008. doi: 10.1038/nm.2207 PMID: 20802499
38. Klieverik LP, Janssen SF, van Riel A, Foppen E, Bisschop PH, Serlie MJ, et al. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc Natl Acad Sci U S A. 2009; 106: 5966-5971. doi: 10.1073/pnas.0805355106 PMID: 19321430
39. Visser WE, Friesema ECH, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol Baltim Md. 2011; 25: 1-14. doi: 10.1210/me.2010-0095
40. Schwabedissen HEM zu, Ware JA, Finkelstein D, Chaudhry AS, Mansell S, Leon-Ponte M, et al. Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. Hepatology. 2011; 54: 644-654. doi: 10.1002/hep.24391 PMID: 21538436
41. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362: 906-916. doi: 10.1056/NEJMoa0905633 PMID: 20220185
42. Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 2000; 141: 3057-3064. PMID: 10965874
43. FOLCH J, LEES M, SLOANE STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226: 497-509. PMID: 13428781